Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475719 | 1.00 | GAA (0.61) | GAAALDH1A1CYP1A2CYP2C9ALOX12 | |
| SCHEMBL14237953 | 1.00 | GAA (0.61) | GAAALDH1A1CYP1A2CYP2C9ALOX12 | |
| SCHEMBL14237937 | 1.00 | GAA (0.61) | GAAALDH1A1CYP1A2CYP2C9ALOX12 | |
| SCHEMBL29034567 | 0.85 | GAA (0.47) | GAAALDH1A1CYP1A2CYP2C9ALOX12 | |
| SCHEMBL14237747 | 0.85 | ALOX12 (0.48) | GAAALDH1A1CYP1A2CYP2C9ALOX12 | |
| SCHEMBL23921486 | 0.83 | GAA (0.52) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL10086616 | 0.82 | PSMB8 (0.32) | ALOX12PSMB8PSMB5 | |
| SCHEMBL17776322 | 0.82 | PSMB8 (0.32) | ALOX12PSMB8PSMB5 | |
| SCHEMBL18751700 | 0.82 | PSMB8 (0.32) | ALOX12PSMB8PSMB5 | |
| SCHEMBL13635161 | 0.82 | PSMB8 (0.32) | ALOX12PSMB8PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239889-A1 | ANTI-CD3-FOLATE CONJUGATES AND THEIR USES | AMBRX, INC. (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239889-A1 | ANTI-CD3-FOLATE CONJUGATES AND THEIR USES | FOLR1, FOLR2, FCGR1A | GAA 497/4885ALDH1A1 1801/4885CYP1A2 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.